This Biotech's Drug Had No 'Red Flags' In Study — Will FDA Panel Agree? [Investor's Business Daily]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Investors Business Daily
Related news Sage Therapeutics ' ( SAGE ) experimental postpartum depression treatment didn't produce any "red flags" in recent tests, an analyst said Tuesday. This is important ahead of a Food and Drug Administration advisory committee meeting, RBC Capital Markets analyst Brian Abrahams said in a note to clients. The meeting will determine whether the benefits of Sage's brexanolone outweigh potential risks, he said. "Overall, we did not find any 'red flags' that would substantially change our view of brexanolone's approvability," he wrote. But there are "some potential hints as to what could be the key discussion topics at an upcoming November FDA panel," he added Brexanolone looks approvable as a postpartum depression treatment, he said. The drug improved insomnia and there were no new or emerging side effects. Blended Phase 2 and Phase 3 data show statistically significant benefits across all time points. Before the FDA considers approving it in December, brexanolone will go befor
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- SAGE ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Sage Therapeutics, Inc. investmentAccesswire
- Major Depressive Disorder Pipeline Insights Report, 2024 Featuring 75+ Companies and Pipeline Drugs, Including SAGE-217 (Sage Therapeutics) and REL-1017 (Relmada Therapeutics) [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics to Participate in Upcoming May Investor ConferencesBusiness Wire
- Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – SAGEAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGEPR Newswire
SAGE
Earnings
- 4/25/24 - Miss
SAGE
Sec Filings
- 4/25/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/24/24 - Form ARS
- SAGE's page on the SEC website